Sensus Healthcare (NASDAQ:SRTS) Earns Buy Rating from Analysts at Lake Street Capital

Lake Street Capital started coverage on shares of Sensus Healthcare (NASDAQ:SRTS) in a report issued on Friday, MarketBeat.com reports. The brokerage issued a buy rating and a $18.00 target price on the stock.

Several other equities analysts have also commented on SRTS. Maxim Group upped their price target on shares of Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. HC Wainwright increased their price objective on shares of Sensus Healthcare from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, November 18th.

Sensus Healthcare Stock Performance

Shares of SRTS stock opened at $8.23 on Friday. Sensus Healthcare has a one year low of $2.91 and a one year high of $9.33. The company has a 50 day moving average price of $7.50 and a 200 day moving average price of $6.84. The firm has a market capitalization of $134.89 million, a price-to-earnings ratio of 14.44 and a beta of 1.21.

Institutional Investors Weigh In On Sensus Healthcare

Several large investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP boosted its stake in shares of Sensus Healthcare by 128.0% in the second quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock valued at $888,000 after purchasing an additional 93,511 shares during the period. Marshall Wace LLP boosted its stake in shares of Sensus Healthcare by 152.4% in the second quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock valued at $412,000 after purchasing an additional 46,732 shares during the period. Cubist Systematic Strategies LLC purchased a new position in shares of Sensus Healthcare in the second quarter valued at $156,000. Truvestments Capital LLC purchased a new position in shares of Sensus Healthcare in the third quarter valued at $32,000. Finally, XTX Topco Ltd boosted its stake in shares of Sensus Healthcare by 76.0% in the third quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after purchasing an additional 13,619 shares during the period. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.